The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Results from a 13-Year Prospective Cohort Study Show Increased Mortality Associated with Bloodstream Infections Caused by Pseudomonas aeruginosa Compared to Other Bacteria
Open accessAbstract
The impact of bacterial species on outcome in bloodstream infections (BSI) is incompletely understood. We evaluated the impact of bacterial species on BSI mortality, with adjustment for patient, bacterial, and treatment factors. From 2002 to 2015, all adult inpatients with monomicrobial BSI caused by Staphylococcus aureus or Gram-negative bacteria at Duke University Medical Center were prospectively enrolled. Kaplan-Meier curves and multivariable Cox regression with propensity score models were used to examine species-specific bacterial BSI mortality. Of the 2,659 enrolled patients, 999 (38%) were infected with S. aureus , and 1,660 (62%) were infected with Gram-negative bacteria. Among patients with Gram-negative BSI, Enterobacteriaceae (81% [1,343/1,660]) were most commonly isolated, followed by non-lactose-fermenting Gram-negative bacteria (16% [262/1,660]). Of the 999 S. aureus BSI isolates, 507 (51%) were methicillin resistant. Of the 1,660 Gram-negative BSI isolates, 500 (30%) were multidrug resistant. The unadjusted time-to-mortality among patients with Gram-negative BSI was shorter than that of patients with S. aureus BSI ( P = 0.003), due to increased mortality in patients with non-lactose-fermenting Gram-negative BSI generally ( P < 0.0001) and Pseudomonas aeruginosa BSI ( n = 158) in particular ( P < 0.0001). After adjustment for patient demographics, medical comorbidities, bacterial antibiotic resistance, timing of appropriate antibiotic therapy, and source control in patients with line-associated BSI, P. aeruginosa BSI remained significantly associated with increased mortality (hazard ratio = 1.435; 95% confidence interval = 1.043 to 1.933; P = 0.02). P. aeruginosa BSI was associated with increased mortality relative to S. aureus or other Gram-negative BSI. This effect persisted after adjustment for patient, bacterial, and treatment factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496
Ibrahim, E. H., Sherman, G., Ward, S., Fraser, V. J., & Kollef, M. H. (2000) · Chest · doi:10.1378/chest.118.1.146 · Cited by 1,779
Cited by
How to manage Pseudomonas aeruginosa infections
Bassetti, M., Vena, A., Croxatto, A., Righi, E., & Guery, B. (2018) · Drugs in Context · doi:10.7573/dic.212527 · Cited by 746
The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update
Reynolds, D., & Kollef, M. (2021) · Drugs · doi:10.1007/s40265-021-01635-6 · Cited by 721
Emergence of antibiotic resistance Pseudomonas aeruginosa in intensive care unit; a critical review
Pachori, P., Gothalwal, R., & Gandhi, P. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.04.001 · Cited by 620
Reyes, J., Komarow, L., Chen, L., Ge, L., Hanson, B. M., Cober, E., Herc, E., Alenazi, T., Kaye, K. S., Garcia-Diaz, J., et al. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00329-9 · Cited by 321
Self-citationPseudomonas aeruginosa: Infections, Animal Modeling, and Therapeutics
Wood, S. J., Kuzel, T. M., & Shafikhani, S. H. (2023) · Cells · doi:10.3390/cells12010199 · Cited by 254
Metadata
- Authors
- Thaden, J. T., Park, L. P., Maskarinec, S. A., Ruffin, F., Fowler, V. G., & van Duin, D.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2017-06
- Volume
- 61
- Issue
- 6
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2604646349
- Cited by
- 168
- References
- 3
- FWCI
- 9.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.